IP Library Granted Patent US 10,501,501
Granted Patent B2
US 10,501,501 · App. 15/758,732 · Granted Dec 10, 2019

Nepovirus coat protein fusion polypeptides and their use

Inventors: Lorene Belval (Colmar, FR); Gerard Demangeat (Ostheim, FR); Caroline Hemmer (Colmar, FR); Christophe Ritzenthaler (Selestat, FR)
Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE DE STRASBOURG; INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
C07K14/005C07K16/00C12N7/00C07K2317/569C07K2319/00C07K2319/60C12N2770/18022C12N2770/18023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,501,501
App. No.
15/758,732
Granted
Dec 10, 2019
Kind
B2
Abstract

The present invention relates to novel fusion polypeptides and the uses thereof. The invention particularly relates to conjugated coat proteins derived from nepoviruses, virus-like particles made with such proteins, and the uses thereof. The particles of the invention can expose and/or encage molecules of interest and have utility in various fields such as the pharmaceutical, agro, or veterinary areas.

Claims (22)

1. A virus-like particle comprising a nepovirus coat protein fused to a compound, wherein the compound is fused to the N-terminus of the nepovirus coat protein and the nepovirus coat protein is a grapevine fanleaf virus (GFLV) coat protein.

2. The particle of claim 1 , further comprising a compound conjugated to a nepovirus coat protein by an anti-coat protein antibody or antibody derivative.

3. The particle of claim 2 , wherein the antibody derivative is a nanobody or an ScFv.

4. The particle of claim 1 , said particle comprising a mixture of nepovirus coat proteins fused to compounds, said mixture comprising a nepovirus coat protein fused via its N-terminus to a compound and a nepovirus coat protein fused to via its C-terminus to a compound.

5. The particle of claim 1 , which comprises an encaged compound fused to the N-terminus of the coat protein, and an exposed compound, conjugated to the surface of the particle by antibody-mediated attachment to a nepovirus coat protein.

6. The particle of claim 1 , said particle being nucleic acid-free.

7. The particle of claim 1 , wherein the coat protein comprises SEQ ID NO: 1.

8. The particle of claim 1 , wherein the first compound is a therapeutic, diagnostic or imaging agent, or a tag.

9. A molecule comprising a nepovirus GFLV coat protein fused to a compound, wherein the compound is fused to the N-terminus of the nepovirus GFLV coat protein and the nepovirus GFLV coat protein comprises SEQ ID NO: 1.

10. A pharmaceutical composition comprising one or more virus-like particles of claim 1 .

11. A pharmaceutical composition comprising the molecule of claim 9 .

12. A method of producing virus-like particles comprising (i) providing a nepovirus GFLV coat protein comprising SEQ ID NO: 1 that is N-terminally fused to a compound, and (ii) allowing said protein, alone or in mixture with other proteins, to assemble into the virus-like particles.

13. The method of claim 12 , further comprising a step (iii) of adding a reactive or active group to the virus-like particles.

14. The method of claim 12 , said method comprising:

(i) providing a nepovirus GFLV coat protein comprising SEQ ID NO: 1 that is N-terminally fused to a first compound,

(ii) allowing said protein, alone or in mixture with other proteins, to assemble into virus-like particles, and

(iii) coupling the particles of (ii) to at least one second compound by antibody-mediated attachment using an anti-coat antibody, or a derivative thereof, conjugated to said second compound.

15. A nucleic acid molecule encoding a molecule of claim 9 .

16. A vector comprising a nucleic acid of claim 15 .

17. A recombinant host cell containing a nucleic acid of claim 15 or a vector comprising said nucleic acid.

18. The particle of claim 2 , wherein the compound is a therapeutic, diagnostic or imaging agent, or a tag.

19. The particle of claim 4 , wherein the compound is a therapeutic, diagnostic or imaging agent, or a tag.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 052469 FRAME 0167. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Apr 28, 2020
From: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
To: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
Reel/Frame 052510/0160 →
CHANGE OF NAME Recorded Apr 22, 2020
From: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
To: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE)
Reel/Frame 052469/0167 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2019
From: RITZENTHALER, CHRISTOPHE
To: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Reel/Frame 048525/0836 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2019
From: DEMANGEAT, GERARD
To: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
Reel/Frame 048514/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2019
From: BELVAL, LORÈNE; HEMMER, CAROLINE
To: UNIVERSITE DE STRASBOURG
Reel/Frame 048514/0630 →